Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Angiocrine Bioscience has raised $2.1M in total funding. The most recent round was Undisclosed. The last funding was announced in September 2025.
Angiocrine Bioscience's investors include California Institute for Regenerative Medicine, Gutbrain Ventures.
Angiocrine Bioscience is headquartered in New York, United States.
Angiocrine Bioscience develops a cellular platform to amplify stem and progenitor cells in both human and mouse models.
Angiocrine Bioscience is at the Undisclosed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Angiocrine Bioscience — Funding & Investors." VCBacked, September 3, 2025, https://www.vcbacked.co/company/angiocrine-bioscience. Accessed August 14, 2026.
VCBacked. (2025). Angiocrine Bioscience — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/angiocrine-bioscience
{{cite web |title=Angiocrine Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/angiocrine-bioscience |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated